摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(6,7,8,9-tetrahydro-9-isopropyl-5,7,7-trimethyl-6-oxo-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-methylbenzamide | 946822-96-4

中文名称
——
中文别名
——
英文名称
4-(6,7,8,9-tetrahydro-9-isopropyl-5,7,7-trimethyl-6-oxo-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-methylbenzamide
英文别名
3-methoxy-N-methyl-4-[(5,7,7-trimethyl-6-oxo-9-propan-2-yl-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzamide
4-(6,7,8,9-tetrahydro-9-isopropyl-5,7,7-trimethyl-6-oxo-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-methylbenzamide化学式
CAS
946822-96-4
化学式
C22H30N6O3
mdl
——
分子量
426.519
InChiKey
PGMLKIGFULHWHO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    99.7
  • 氢给体数:
    2
  • 氢受体数:
    7

文献信息

  • Dihydrodiazepines useful as inhibitors of protein kinases
    申请人:Kay David
    公开号:US20080167289A1
    公开(公告)日:2008-07-10
    The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    本发明涉及一种作为蛋白激酶抑制剂的化合物。该发明还提供包含所述化合物的药用合适组合物,并提供使用这些组合物在治疗各种疾病、状况或障碍中的方法。该发明还提供制备本发明化合物的方法。
  • [EN] METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE DÉRIVÉS DE PYRIMIDINE UTILES COMME INHIBITEURS DE LA PROTÉINE KINASE
    申请人:VERTEX PHARMA
    公开号:WO2011036566A1
    公开(公告)日:2011-03-31
    A method of preparing a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the steps of: a) reacting a compound represented by Structural Formula (A) with FTNR1R7 under suitable conditions to form a compound represented by Structural Formula (B); and b) i) when R12 is -NO2, and R11 is -OR14: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form a compound represented by Structural Formula (II); and 2) optionally reacting the compound represented by Structural Formula (II) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I), wherein R8 is R9; or ii) when R12 is halogen, and R11 is -NHR13: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form the compound represented by Structural Formula (I); and 2) optionally, when R13 is - H, reacting the compound produced from step b), ii), 1) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I) wherein R8 is R9.
    一种制备化合物结构式(I)或其药学上可接受的盐的方法,其中结构式(I)中的变量如说明书和权利要求中所述,包括以下步骤:a)在适当的条件下,将化合物结构式(A)与FTNR1R7反应,形成化合物结构式(B);和b)i)当R12为-N02,而R11为-OR14时:1)在适当的环化条件下,使化合物结构式(B)环化形成化合物结构式(II);和2)可选择地将化合物结构式(II)与R9-LG2反应,其中LG2是适当的离去基团,形成化合物结构式(I),其中R8为R9;或ii)当R12为卤素,而R11为-NHR13时:1)在适当的环化条件下,使化合物结构式(B)环化形成化合物结构式(I);和2)可选择地,当R13为-H时,将从步骤b)ii)1)产生的化合物与R9-LG2反应,其中LG2是适当的离去基团,形成化合物结构式(I),其中R8为R9。
  • DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES
    申请人:Kay David
    公开号:US20100190765A1
    公开(公告)日:2010-07-29
    The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    本发明涉及一种作为蛋白激酶抑制剂有用的化合物。该发明还提供包括所述化合物的药学上可接受的组合物,并且提供使用这些组合物治疗各种疾病、状况或障碍的方法。该发明还提供制备本发明化合物的方法。
  • METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS
    申请人:Charrier Jean-Damien
    公开号:US20120271045A1
    公开(公告)日:2012-10-25
    A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims. Additionally, the present invention relates to compounds of Structural Formula (I), which are useful as inhibitors of protein kinase.
    一种制备结构式(I)所代表的化合物或其药学上可接受的盐的方法,其中结构式(I)的变量如规范和权利要求所述。此外,本发明涉及结构式(I)的化合物,其作为蛋白激酶抑制剂是有用的。
  • US7622463B2
    申请人:——
    公开号:US7622463B2
    公开(公告)日:2009-11-24
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)